Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 14/20 | 0.80 |
| ▸ | HEXA | P06865 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22111983 | 0.93 | ASGR1 (0.82) | ASGR1HEXA | |
| SCHEMBL23723841 | 0.90 | ASGR1 (0.80) | ASGR1 | |
| SCHEMBL22021760 | 0.90 | ASGR1 (0.77) | ASGR1 | |
| SCHEMBL17256301 | 0.88 | ASGR1 (1.00) | ASGR1 | |
| SCHEMBL20577240 | 0.88 | ASGR1 (0.65) | ASGR1 | |
| SCHEMBL30870105 | 0.88 | ASGR1 (0.63) | ASGR1 | |
| SCHEMBL22076553 | 0.87 | ASGR1 (0.64) | ASGR1 | |
| SCHEMBL20577598 | 0.87 | ASGR1 (0.73) | ASGR1 | |
| SCHEMBL27228142 | 0.86 | ASGR1 (0.69) | ASGR1 | |
| SCHEMBL22112323 | 0.86 | ASGR1 (0.63) | ASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-05 | — | — | US | disclosed |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-20240109931-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-04 | — | — | US | disclosed |
| US-11597927-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-07 | — | — | US | disclosed |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | PFIZER INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | PFIZER INC. | 2021-07-01 | — | — | US | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-06-18 | — | — | US | disclosed |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-05-21 | — | — | US | disclosed |
| EP-3630788-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2020-04-08 | — | — | EP | disclosed |
| EP-3630789-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018223081-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018223073-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | NSUN3, METTL3, RNASE1 | ASGR1 596/4885HEXA 860/4885 |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ASGR1 569/4885HEXA 482/4885 |
| US-20200190515-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ASGR1 569/4885HEXA 482/4885 |
| US-20240109931-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | ASGR1 437/4885HEXA 398/4885 |
| US-11597927-B2 | Oligonucleotide compositions and methods of use thereof | RNASE1, RNASEH1, NSUN3 | ASGR1 608/4885HEXA 459/4885 |
| US-20200157545-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | ASGR1 385/4885HEXA 373/4885 |
| US-20210198305-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | ASGR1 437/4885HEXA 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.